Fig. 8: Targeting the SOX13–SCAF1 pathway potentiates the antitumor activity of immunotherapy. | Nature Communications

Fig. 8: Targeting the SOX13–SCAF1 pathway potentiates the antitumor activity of immunotherapy.

From: Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer

Fig. 8

A SOX13-KO (sg-SOX13), SCAF1-overexpressing (Lv-SCAF1) or control YTH16 (m) cells were grown as xenografts. Antibody to mouse PD1 treatment or lipoxstatin alone or in combination started on Day 7 after injection of C57BL/6 mice with cells to form xenografts. Tumor growth (B) and weight change (C) are shown (n = 4 mice per group). Data are presented as mean values ± SD. D Flow cytometry analysis of BODIPY fluorescence in CD45+ and CD45− tumor cells isolated from control YTH16 (m) derived xenografts treated with antibody to mouse PD1. E Representative flow cytometry analysis and quantification of BODIPY fluorescence in CD45− tumor cells from YTH16 (m)-derived xenografts with the treatment described above (data from randomly selected three tumors from each group). Data are presented as mean values ± SD. Statistical significance in (B,C,E) is determined by two-tailed unpaired t-test. Source data are provided as a Source Data file.

Back to article page